It is now clear that vitamin D has important roles in addition to its classic effects on calcium and bone homeostasis. As the vitamin D receptor is expressed on immune cells (B cells, T cells, and antigen-presenting cells), and these immunologic cells are all capable of synthesizing the active vitamin D metabolite, vitamin D has the capability of acting in an autocrine manner in a local immunologic milieu. Vitamin D can modulate the innate and adaptive immune responses. Deficiency in vitamin D is associated with increased autoimmunity and an increased susceptibility to infection. As immune cells in autoimmune diseases are responsive to the ameliorative effects of vitamin D, the beneficial effects of supplementing vitamin D-deficient individuals with autoimmune disease may extend beyond the effects on bone and calcium homeostasis.
HolickMF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–281.
2.
BikleD. Nonclassic actions of vitamin D. J Clin Endocrinol Metab. 2009;94(1):26–34.
3.
TownsendK, EvansKN, CampbellMJ, . Biological actions of extra-renal 25-hydroxyvitamin D-1alpha-hydroxylase and implications for chemoprevention and treatment. J Steroid Biochem Mol Biol. 2005;97(1-2):103–109.
4.
NagpalS, NaS, RathnachalamR. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev. 2005;26(5):662–687.
5.
WuS, RenS, NguyenL, . Splice variants of the CYP27b1 gene and the regulation of 1,25-dihydroxyvitamin D3 production. Endocrinology. 2007;148(7):3410–3418.
6.
van EttenE, StoffelsK, GysemansC, . Regulation of vitamin D homeostasis: implications for the immune system. Nutr Rev. 2008;66(10 suppl 2):S125–S134.
7.
WilliamsC. On the use and administration of cod-liver oil in pulmonary consumption. Lond J Med. 1849;1:1–18.
8.
GindeAA, MansbachJM, CamargoCAJr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2009;169(4):384–390.
9.
LaaksiI, RuoholaJP, TuohimaaP, . An association of serum vitamin D concentrations G 40 nmol/L with acute respiratory tract infection in young Finnish men. Am J Clin Nutr. 2007;86(3):714–717.
10.
CannellJJ, ViethR, UmhauJC, . Epidemic influenza and vitamin D. Epidemiol Infect. 2006;134(6):1129–1140.
11.
BodnarLM, KrohnMA, SimhanHN. Maternal vitamin D deficiency is associated with bacterial vaginosis in the first trimester of pregnancy. J Nutr. 2009;139(6):1157–1161.
12.
VillamorE. A potential role for vitamin D on HIV infection?Nutr Rev. 2006;64(5 Pt 1):226–233.
13.
RodriguezM, DanielsB, GunawardeneS, . High frequency of vitamin D deficiency in ambulatory HIV-positive patients. AIDS Res Hum Retroviruses. 2009;25(1):9–14.
14.
YamshchikovAV, DesaiNS, BlumbergHM, . Vitamin D for treatment and prevention of infectious diseases: a systematic review of randomized controlled trials. Endocr Pract. 2009;15(5):438–449.
15.
UrashimaM, SegawaT, OkazakiM, . Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am J Clin Nutr. 2010;91(5):1255–1260.
16.
GalloRL, MurakamiM, OhtakeT, . Biology and clinical relevance of naturally occurring antimicrobial peptides. J Allergy Clin Immunol. 2002;110(6):823–831.
17.
LiuPT, StengerS, LiH, . Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311(5768):1770–1773.
18.
WangTT, NestelFP, BourdeauV, . Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004;173(5):2909–2912.
19.
LiuPT, SchenkM, WalkerVP, . Convergence of IL-1beta and VDR activation pathways in human TLR2/1-induced antimicrobial responses. PLoS One. 2009;4(6):e5810.
20.
AdoriniL. Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell Immunol. 2005;233(2):115–124.
21.
MungerKL, LevinLI, HollisBW, . Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296(23):2832–2838.
22.
LittorinB, BlomP, ScholinA, . Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: results from the nationwide Diabetes Incidence Study in Sweden (DISS). Diabetologia. 2006;49(12):2847–2852.
23.
MerlinoLA, CurtisJ, MikulsTR, . Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum. 2004;50(1):72–77.
24.
FronczakCM, BaronAE, ChaseHP, . In utero dietary exposures and risk of islet autoimmunity in children. Diabetes Care. 2003;26(12):3237–3242.
25.
ZoldE, SzodorayP, GaalJ, . Vitamin D deficiency in undifferentiated connective tissue disease. Arthritis Res Ther. 2008;10(5):R123.
26.
KamenD, AranowC. Vitamin D in systemic lupus erythematosus. Curr Opin Rheumatol. 2008;20(5):532–537.
27.
CorrealeJ, YsrraelitMC, GaitanMI. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain. 2009;132(Pt 5):1146–1160.
28.
SmoldersJ, MenheereP, KesselsA, . Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler. 2008;14(9):1220–1224.
29.
CraigSM, YuF, CurtisJR, . Vitamin D status and its associations with disease activity and severity in African Americans with recent-onset rheumatoid arthritis. J Rheumatol. 2010;37(2):275–281.
30.
PatelS, FarragherT, BerryJ, . Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheum. 2007;56(7):2143–2149.
31.
LemireJM, AdamsJS, SakaiR, . 1 alpha, 25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J Clin Invest. 1984;74(2):657–661.
32.
ChenS, SimsGP, ChenXX, . Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol. 2007;179(3):1634–1647.
MattnerF, SmiroldoS, GalbiatiF, . Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D(3). Eur J Immunol. 2000;30(2):498–508.
35.
BoonstraA, BarratFJ, CrainC, . 1alpha, 25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol. 2001;167(9):4974–4980.
36.
TangJ, ZhouR, LugerD, . Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J Immunol. 2009;182(8):4624–4632.
37.
DanielC, SartoryNA, ZahnN, . Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther. 2008;324(1):23–33.
38.
GregoriS, CasoratiM, AmuchasteguiS, . Regulatory T cells induced by 1 alpha, 25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol. 2001;167(4):1945–1953.
39.
BarratFJ, CuaDJ, BoonstraA, . In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med. 2002;195(5):603–616.
40.
GormanS, KuritzkyLA, JudgeMA, . Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes. J Immunol. 2007;179(9):6273–6283.
41.
PennaG, RoncariA, AmuchasteguiS, . Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3. Blood. 2005;106(10):3490–3497.
42.
AlmerighiC, SinistroA, CavazzaA, . 1Alpha, 25-dihydroxyvitamin D3 inhibits CD40L-induced pro-inflammatory and immunomodulatory activity in human monocytes. Cytokine. 2009;45(3):190–197.
43.
PiemontiL, MontiP, SironiM, . Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol. 2000;164(9):4443–4451.
44.
GriffinMD, LutzW, PhanVA, . Dendritic cell modulation by 1alpha, 25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci U S A. 2001;98(12):6800–6805.
45.
SzelesL, KeresztesG, TorocsikD, . 1,25-dihydroxyvitamin D3 is an autonomous regulator of the transcriptional changes leading to a tolerogenic dendritic cell phenotype. J Immunol. 2009;182(4):2074–2083.
46.
Linker-IsraeliM, ElstnerE, KlinenbergJR, . Vitamin D(3) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMC. Clin Immunol. 2001;99(1):82–93.
47.
DuT, ZhouZG, YouS, . Modulation of monocyte hyperresponsiveness to TLR ligands by 1,25-dihydroxy-vitamin D3 from LADA and T2DM. Diabetes Res Clin Pract. 2009;83(2):208–214.
48.
Ben-ZviI, AranowC, MackayM, . The impact of vitamin D on dendritic cell function in patients with systemic lupus erythematosus. PLoS One. 2010;5(2):e9193.
49.
BennettL, PaluckaAK, ArceE, . Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197(6):711–723.
50.
BaechlerEC, BatliwallaFM, KarypisG, . Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100(5):2610–2615.
51.
KirouKA, LeeC, GeorgeS, . Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005;52(5):1491–1503.
52.
FengX, WuH, GrossmanJM, . Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54(9):2951–2962.
